Hasthisreporthelpedtohoneourapproachtothemanagementofpatientswithmetastaticcolorectalcancer?There aremanyreportsofregimensthatdeliveririnotecanandoxaliplatin on the same day with either 5-FU or capecitabine suchastheFOLFOXIRIregimenadvocatedbyFalconeetal. [3] . Other groups have alternated various 5-FU or capecitabineplusirinotecanregimenssuchasFOLFIRIwith 5-FUplusoxaliplatinregimenssuchasoneoftheFOLFOX regimens delivering each combination once a month on a 2-weekalternatingschedule [4, 5] .Allhaveledtosimilaroutcomes and there are no clear data to make a determination whetheroneapproachshouldbepreferredoveranother.
Thisregimen'svariationonthosethemesistoalternateirinotecanandoxaliplatinweeklyratherthaneveryotherweek. Onecouldpostulatethatthealternatingapproachcouldbean effective strategy to moderate toxicity because of the interruptedexposuretothesideeffectsofirinotecanperhapslesseningitsassociatedalopeciaanddiarrheaandinterruptedexposuretothesideeffectsofoxaliplatinperhapseasingtheassociated neuropathy and myelosuppression. Others might theorize that cytotoxic drugs work best against cancer cells whengivenasoftenaspossibleatashighdosesaspossibleto minimizethechancesoftumorcellsdevelopingearlydrugresistanceasaconsequenceofnonlethaldamage.Proponentsof thatapproachwouldnotalternateregimensbutinsteadmove fromonetothenextwhenthetumorprogresses.It'snotclear thateitherofthosetheoreticalissueshavepracticalimplicationsonanindividualpatient'slikelihoodofaresponse,qualityoflife,ortheirlongevity.
IntheendIwouldassertthatthisstudywillhave,atbest, a modest impact on the quest to improve patient care for At nearly every conference on the treatment of metastatic coloncancertheorganizersengageanopinionleadertoaddress whether it is more effective to deploy chemotherapy agentsallatonceinanattemptatmaximalresponseortoadministersingleordoubleagentstoextendoptions,moderate toxicity,andmitigatethecostsoftreatment.Atthepodium, intheliterature,andinpracticethereareproponentsofboth approaches, but those advocating mass tumor cell murder seemtooutnumberthosewhoprefertheserialkilleroption thesedays.Alsoatthepodiumthereislikelytobeanopinion leader who is engaged to consider the merits of infusing 5-fluorouracil (5-FU) compared to substitution of capecitabineoralternativeoralagentsforit.
InthereportbyvonMoosetal.inthisissueofOnkOlOgie the investigators embrace the philosophy of administering three cytotoxic agents at once and set out to find a safe capecitabine dose to substitute for 5-FU infusion [1] . Their workisalogicalsuccessortoapriorSAKKphaseI-IIstudy inwhichoxaliplatinandirinotecanwereadministeredonalternatingweekswith5-FUasthecommoncompaniongiven weekly [2] . Patients enrolled in that trial had a promising overallsurvivalexceeding25monthswithouttheuseofafirst line biologic agent, although the sample size was small and this favorable outcome may not hold up if the regimen was testedinalargerpopulationofpatients.
Inthisefforttheoxaliplatinandirinotecandosesimported fromthattrialwerefixedandthemissionwastoestablisha safedoseofcapecitabine.Theinvestigatorsdidthatbyenrolling23patientsat6centersinwhatappearstobeawellcon-ductedstudyaswouldbeexpectedfromthisgroupofexperienced investigators. Despite the combination of 3 cytotoxic agentstoxicitywasmoderate.OnecouldarguewhethermyocardialfibrosisandMeniere'sdiseasearereallydoselimiting toxicities related to this regimen and if the dose level could havebeenpushedabithigher.Onecouldalsoassertthatina Goldberg individuals with metastatic colon cancer. It is likely that thosewhoembracetheuseofthreecytotoxicagentsatonce will opt for FOLFOXIRI as there is phase III experience withthatregimen.Forthesamereasonsthosewhopreferan alternating approach will opt for alternating a variation of FOLFOX with FOLFIRI or CapeOx with CapeIri. A few oncologistswillstillprobablyhaveapreferencetoadminister serial single agents. Most oncologists will also consider addingabiologicagenttofirstlinetherapy.Itseemsthatthe argumentswehaveaboutusingmorecytotoxicagentsversus theserialuseofcytotoxicagentsandaboutoralversusintravenous 5-FU parallel political arguments on managing terrorism.Discussingwhetheritisbettertoadopta'shockand awe'approachorto'targettheterroristsoneatatime'isnot verysatisfyingapproachtoeradicatingpoliticalconflictand likewiseinthewaragainstcanceranemphasisonfinetuning cytotoxic regimens in advanced colorectal cancer seems somewhat unrewarding. The pointis that we need tothink differently.Wemustindividualizemanagementapproaches based upon a better understanding of the heterogeneous nature of colorectal tumors rather than assuming all are alike.Wehavetopracticallyexploitthegrowingrecognition ofvariablepatientbiology(pharmacogenetics).Andfinally we should prioritize the testing of new agents rather than to keep fiddling with variations on our current tactical approaches.
